In Reply We appreciate the comments from van Rossum et al in response to our recent randomized clinical trial on the efficacy of endocrine therapy for treatment of breast cancer in men.1 We investigated the extent of estradiol change in male patients with breast cancer receiving different kinds of endocrine therapies (tamoxifen, tamoxifen plus gonadotropin-releasing hormone analogue [GnRHa] or exemestane plus GnRHa) as the primary objective. Secondary objectives were changes in other sexual hormone parameters, libido, and quality of life, as well as adverse effects.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Reinisch M, Thode C, Loibl S. Reporting the Analytical Method Is Essential to Assessing Studies in Which Biomarkers Are a Major Study Objective—Reply. JAMA Oncol. 2021;7(9):1403–1404. doi:10.1001/jamaoncol.2021.2046
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.